MARKET OVERVIEW
Antihyperlipidemic drugs work to lower blood lipid levels and lower the risk of heart disease, pulmonary artery disease, and high cholesterol. These medications also assist the body to get rid of extra lipids in the faeces by reducing lipid absorption. Antihyperlipidemic medications are frequently prescribed by doctors with other medications to increase good cholesterol levels and decrease bad cholesterol levels. A patient's cholesterol profile and other underlying conditions allow doctors to choose the optimal antihyperlipidemic treatment from various options. Statins are the most extensively used antihyperlipidemic medication. Patients can use niacin, fibrates, and bile acid sequestrants based on the body's lipid levels. These antihyperlipidemic medications all work in different ways; some may take weeks to affect the body, while others might have negative side effects. Doctors prefer to use conservative measures to treat patients with unusually high lipid, including modification in diet and activity. This is the best way to restore the patient's ideal health and physical condition. However, if these approaches are ineffective, doctors will prescribe antihyperlipidemic medications and modify the dosage based on the patient's recovery.
The demand for antihyperlipidemic drugs is on the rise due to the increase in sedentary lifestyles across the globe. Additionally, surge in heart disease and stroke risk factors with elevated cholesterol levels are further expected to contribute the market growth. High cholesterol contributes to one-third of ischemic heart disease cases worldwide. According to WHO, elevated cholesterol contributes to 29.7 million DALYS, or 2% of all DALYS, and 2.6 million fatalities (4.5% of all deaths). Moreover, increasing awareness related to the use of antihyperlipidemic drugs also drives the antihyperlipidemic drugs market growth in the near future.
MARKET SCOPE
The “Global antihyperlipidemic drugs market analysis to 2031” is a specialized and in-depth study of the pharmaceutical industry with a special focus on global market trend analysis. The report aims to provide an overview of the antihyperlipidemic drugs market with detailed market segmentation by drug class, distribution channel, and geography. The report provides key statistics on the market status of the leading antihyperlipidemic drugs market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The antihyperlipidemic drugs market is segmented based on drug class, distribution channel, and region. Based on drug class, the global antihyperlipidemic drugs market is differentiated into statins, bile acid sequestrants, cholesterol absorption inhibitor, fibric acid dervivatives, PCSK9 Inhibitors, combination, and others. By distribution channel, the antihyperlipidemic drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
MARKET DYNAMICS
Drivers-
The American Heart Association claims that after the age of 20, cholesterol levels gradually rise. They often begin to decline after the age of 70 for women and 60 for men. In addition, women of all ages typically have mean HDL-C levels about 10mg/dl greater than all men. The advent of new drug classes for nonstatin users, an increase in the number of statin users, and recommendations for the use of antihyperlipidemics to reduce the risk of cardiovascular diseases (CVD) are some of the causes that are projected to boost the market. The U.S. hyperlipidemia guidelines, which address the dosage regimen of statins for patients over the age of 21 are at risk of developing atherosclerotic cardiovascular disease (ASCVD), that are crucial to the antihyperlipidemic drugs market's expansion. As a result, new comorbidities of high cholesterol and triglyceride levels are becoming part of the target group for statins. The majority of antihyperlipidemic medications have mild side effects. However, some medications have a high risk of having severe side effects, like type 2 diabetes or liver damage. Even in the later stages of studies, drug classes like CETP inhibitors have been dropped or discontinued because of side effects or an inability to provide sufficient outcomes. Hence, risks associated with antihyperlipidemics pose a major challenge to their entry into the antihyperlipidemic drugs market.
REGIONAL FRAMEWORK
The market for antihyperlipidemic medications is dominated by the North American region, which held the greatest antihyperlipidemic drugs market market share in 2022. The market for antihyperlipidemic medications in North America is expected to grow due to the increased incidence of cardiovascular disorders and stokes. For instance, in the United States, there are around 795,000 strokes per year. Thus, increasing cases of strokes drive the regional growth for antihyperlipidemic drugs market. Over the past several years, the demand for antihyperlipidemic medications has increased in U.S. owing to excessive lipid levels that can cause several illnesses, including artery blockages and plaques, which can have life-threatening consequences.
Europe was the second leading revenue contributor in the global antihyperlipidemic drugs market market. the region is expected to closely follow North America during the forecast period owing to the high frequency of hyperlipidemia in the region. Moreover, lifestyle choices or underlying medical disorders are the main contributors of hyperlipidemia. It is hypothesised that lifestyle factors such as obesity, smoking, and inactivity will cause hyperlipidemia and diseases such as Kidney disease, diabetes, and other illnesses are prone to cause hyperlipidemia. Furthermore, surge in geriatric population is also expected to contribute the rising prevelance of hyperlipidemic as the eldely population is more prone to various disorders such as cardiovascular disorders, kidney disease, and other and are likely to drive growth in the market for antihyperlipidemic medications worldwide.
Antihyperlipidemic Drugs Market Report Analysis
CAGR (2023 - 2031)
US$ XX Million
US$ XX Million
Report Coverage
Key Players
Regional Overview
Market Segmentation
By Drug Class
By Distribution Channel
The report covers key antihyperlipidemic drugs market developments, such as organic and inorganic growth strategies. Various companies such as Abbvie, Amgen, Inc, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Dr. Reddy's Laboratories, Merck & Co. Inc., Novartis AG, Mylan N.V., Pfizer, and among others are focusing on organic growth strategies such as product launches, product approvals, and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, partnerships & collaborations. These activities have paved the way for the expansion of business and the customer base of market players. The market players from the antihyperlipidemic drugs market are anticipated to have lucrative growth opportunities with the rising demand for pain management therapeutics in the global market.
Key Developments in the Global Antihyperlipidemic drugs market
- In August 2022, The American College of Cardiology (ACC) task force on expert consensus decision pathways (ECDP) recommended bempedoic acid (NEXLETOL) as a significant oral non-statin therapy for LDL-cholesterol (LDL-C) lowering in the management of atherosclerotic cardiovascular disease (ASCVD), according to Esperion.
- In May 2022, Sun Pharma launched oral lipid lowering agent in India. It is recommended for persons with heart disease who are taking the maximum acceptable dose of statins and those with hereditary genetic disorders that raise cholesterol levels.
- In May 2022, Zydus Lifesciences Limited launched Bemdac (Bempedoic acid), a new class of oral drug in India. The medication introduces a new line of treatment for those with uncontrolled LDL-cholesterol (LDL-c) levels despite lifestyle changes and the administration of maximum tolerated doses of statins, which are the current line of treatment and the cornerstone of managing dyslipidemia.
- In December 2019, Novartis received US Food and Drug Administration (FDA) approval for Leqvio (inclisiran), a first-in-class siRNA to lower cholesterol.
The report also includes key companies' profiles, their SWOT analysis, and antihyperlipidemic drugs market size in the antihyperlipidemic drugs market . In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information for the last three years, and key development in the past five years.
The Insight Partner’s dedicated research and analysis team comprises experienced professionals with advanced statistical expertise and offers various customization options in the current study.
Antihyperlipidemic Drugs Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ XX Million |
| Market Size by 2031 | US$ XX Million |
| Global CAGR (2023 - 2031) | XX% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Drug Class
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies
1. ABBVIE
2. AMGEN INC.
3. ASTRAZENECA PLC.,
4. BRISTOL-MAYERS SQUIBB COMPANY
5. MERCK AND CO., INC.,
6. NOVARTIS AG
7. SANOFI S.A.,
8. PFIZER, INC.
9. MYLAN NV.
10. DR. REDDY'S LABORATORIES LTD
Get Free Sample For